Scientific Poster Download

The evolution of Antibody-Drug Conjugates (ADCs) from traditional cytotoxic agents to next-generation bioconjugates has significantly increased the complexity of molecular design. Conventional “one-size-fits-all” conjugation methods often struggle with sub-optimal therapeutic indices, drug resistance, and unpredictable pharmacokinetic profiles. To address these challenges, there is a critical need for integrated platforms capable of precise, modular customization. WuXi XDC has built an integrated bioconjugate discovery platform that includes antibody, payload-linker and ADC/bioconjugate preparation, in vitro/in vivo characterization, and developability assessment.

By leveraging our optimized payload-linker customization platform, we enable clients to rapidly acquire tailor-made components during the bioconjugates discovery stage. This streamlined approach significantly accelerates bioconjugates drug discovery, shortens development cycles, and ensures the efficient advancement toward PCC (Preclinical Candidate) nomination with diverse new modalities.